Overview

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and toxicity of dose-adjusted EPOCH-R in patients with MYC positive diffuse large B-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Cyclophosphamide
Doxorubicin
Etoposide
Prednisone
Rituximab
Vincristine